ALKYLAMINE - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.3
| Stock Code | ALKYLAMINE | Market Cap | 8,841 Cr. | Current Price | 1,729 ₹ | High / Low | 2,449 ₹ |
| Stock P/E | 49.1 | Book Value | 300 ₹ | Dividend Yield | 0.58 % | ROCE | 16.6 % |
| ROE | 12.3 % | Face Value | 2.00 ₹ | DMA 50 | 1,559 ₹ | DMA 200 | 1,654 ₹ |
| Chg in FII Hold | 0.00 % | Chg in DII Hold | 0.00 % | PAT Qtr | 45.4 Cr. | PAT Prev Qtr | 42.3 Cr. |
| RSI | 59.4 | MACD | 77.1 | Volume | 60,223 | Avg Vol 1Wk | 1,39,700 |
| Low price | 1,212 ₹ | High price | 2,449 ₹ | PEG Ratio | -6.09 | Debt to equity | 0.00 |
| 52w Index | 41.8 % | Qtr Profit Var | -1.41 % | EPS | 35.2 ₹ | Industry PE | 29.2 |
📊 Financial Overview:
ALKYLAMINE shows moderate fundamentals with quarterly PAT at ₹45.4 Cr., slightly higher than the previous ₹42.3 Cr. ROCE at 16.6% and ROE at 12.3% indicate average capital efficiency. Debt-to-equity is 0.00, which is positive, ensuring financial stability. EPS stands at ₹35.2, reflecting modest profitability. However, quarterly profit variation (-1.41%) suggests stagnation in earnings momentum.
💹 Valuation Indicators:
The stock trades at a P/E of 49.1, well above the industry average of 29.2, indicating overvaluation. P/B ratio is ~5.8 (1729 ÷ 300), which is elevated. PEG ratio is negative (-6.09), reflecting weak growth prospects relative to valuation. Dividend yield of 0.58% provides minor investor returns. Intrinsic value appears lower than current price, limiting upside potential.
🏢 Business Model & Advantage:
ALKYLAMINE operates in specialty chemicals, particularly amines, which are critical inputs for pharmaceuticals and agrochemicals. Its competitive advantage lies in niche product offerings and a debt-free balance sheet. However, weak return metrics and high valuations limit overall health. Institutional sentiment remains neutral, with no significant changes in FII or DII holdings.
📈 Entry Zone:
Technically, support lies near ₹1,559 (50 DMA) and ₹1,654 (200 DMA). A cautious entry zone would be between ₹1,550–₹1,650 if valuations cool down. Long-term holding requires improvement in profitability and efficiency ratios before confidence can be restored.
Positive
- 📌 Debt-free balance sheet (Debt-to-equity 0.00).
- 📌 EPS of ₹35.2 reflects consistent profitability.
- 📌 Specialty chemicals niche provides industry relevance.
Limitation
- ⚠️ High P/E (49.1) compared to industry average (29.2).
- ⚠️ Weak ROE (12.3%) and moderate ROCE (16.6%).
- ⚠️ Negative PEG ratio (-6.09) indicates poor growth prospects.
- ⚠️ Quarterly profit variation (-1.41%) shows stagnation.
Company Negative News
- 📰 No major negative news reported, but weak growth and high valuation are concerns.
Company Positive News
- 📰 Debt-free structure provides financial resilience.
- 📰 Stable EPS and niche product portfolio support long-term relevance.
Industry
- 🌐 Specialty chemicals industry benefits from demand in pharma and agrochemicals.
- 🌐 Industry P/E at 29.2 reflects growth potential, but ALKYLAMINE trades at a steep premium.
Conclusion
✅ ALKYLAMINE benefits from a debt-free balance sheet and niche industry positioning. However, weak return ratios, stagnant profits, and stretched valuations make it risky for fresh entry. Entry is only advisable near support levels (₹1,550–₹1,650) with caution. Long-term holding requires improvement in profitability and efficiency to justify sustained investment.
For a broader perspective, you could explore a peer comparison or a specialty chemicals sector outlook to see how ALKYLAMINE stacks up against competitors.